Stockreport

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

Immix Biopharma, Inc.  (IMMX) 
PDF LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pi [Read more]